• News & Events  > 

PRESS RELEASES.

December 9, 2024
Notch at ASH: A Layered Cloaking Strategy to Generate Allogeneic iPSC-Derived CD8 T-Cells That Evade NK Clearance

December 9, 2024
Notch at ASH: A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo Persistence of Allogeneic iPSC Derived CD8 T-Cells

November 5, 2024
Notch Therapeutics Signals a New Era in CAR-T Therapies

July 10, 2024
Notch at ISSCR: A Platform for Rapid and Efficient Engineering of Multi-edited Clonal iPSC Lines for Allogeneic T Cell Therapies

May 29, 2024
Notch at ISCT: Generation of Functional CD8+ T Cells from iPSCs in a Scalable Stirred Tank Bioreactor via Notch Signaling Provided by DLL4/VCAM-coupled Microbeads to Support the Development of Off-the-shelf CAR-T Cell Therapeutics

April 5, 2024
Notch at AACR Annual Meeting: Preclinical in Vitro and in Vivo Evaluation of CD8αβ+ CD19 CAR iPSC T Cells Generated in a TCR Signal Independent Manner Using DLL4/VCAM-coupled Microbeads

March 28, 2023
Notch Therapeutics Promotes Chris Bond to Chief Scientific Officer

February 27, 2023
Notch Researchers Develop Improved Model for Predicting CAR-T Clinical Pharmacology and Response to Advance Next-Generation Product Design; Results Published in Nature Biotechnology

November 8, 2022
Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

September 14, 2022
University of British Columbia Research Team Develops Accelerated Process for Producing T Cells from Human Stem Cells for Manufacturing Cell Therapies; Advancement Enhances Notch Technology Platform

April 6, 2022
Notch Therapeutics Welcomes Deepika Rajesh as VP, Stem Cell Biology & Developmental Immunology

January 6, 2022
Notch Therapeutics’ Peter Zandstra Appointed to the Order of Canada

August 18, 2021
Notch Therapeutics Scientific Co-Founder Recognized in Nature Communications Publication Describing the Company’s Foundational Technology for Generating T Cells from Renewable Sources

August 6, 2021
Notch Therapeutics Named 2021 Emerging Life Sciences Company of the Year by Life Sciences BC

June 18, 2021
Notch Therapeutics Participates as Sponsor and Presenter at ISSCR 2021 Virtual Meeting

February 10, 2021
Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

January 25, 2021
Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences

October 19, 2020
Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development

July 20, 2020
Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company’s Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics

November 5, 2019
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

---